Optic nerve crush: Protection and regeneration

Brain Research Bulletin

Volumn 62, Issue 6, 2004, Pages 467-471

  Schwartz, Michal ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Autoimmune; T cells; Vaccination

Indexed keywords

GLATIRAMER; GLUTAMIC ACID; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

AUTOIMMUNE DISEASE; CELL DAMAGE; CELL DEATH; CELL TRANSPLANTATION; CELLULAR IMMUNITY; CONFERENCE PAPER; DISEASE MODEL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; INTRAOCULAR PRESSURE ABNORMALITY; MACROPHAGE; MULTIPLE SCLEROSIS; NERVE FIBER REGENERATION; NEUROPROTECTION; NONHUMAN; OPTIC NERVE INJURY; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SPINAL CORD INJURY;

EID: 1342291355     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(03)00076-5     Document Type: Conference Paper

References (61)

1. Ahmed F.A., Chaudhary P., Sharma S.C. Effects of increased intraocular pressure on rat retinal ganglion cells. Int. J. Dev. Neurosci. 19:2001;209-218.
2. S. Bakalash, T. Mizrahi, A. Kessler, R. Nussenblatt, M. Schwartz, Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma, Invest. Opthalmol. Vis. Sci. (2003) in press.
3. Brubaker R.F. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 121:1996;473-483.
4. Bruno V., Scapagnini U., Canonico P.L. Excitatory amino acids and neurotoxicity. Funct. Neurol. 8:1993;279-292.
5. Cadelli D.S., Schwab M.E. Myelin-associated inhibitors of neurite outgrowth and their role in CNS regeneration. Ann. N.Y. Acad. Sci. 633:1991;234-240.
6. Connaughton V.P., Behar T.N., Liu W.L., Massey S.C. Immunocytochemical localization of excitatory and inhibitory neurotransmitters in the zebrafish retina. Vis. Neurosci. 16:1999;483-490.
7. Davanger S., Ottersen O.P., Storm-Mathisen J. Glutamate, GABA, and glycine in the human retina: an immunocytochemical investigation. J. Comp. Neurol. 311:1991;483-494.
8. Dreyer E.B., Grosskreutz C.L. Excitatory mechanisms in retinal ganglion cell death in primary open angle glaucoma (POAG). Clin. Neurosci. 4:1997;270-273.
9. Dreyer E.B., Pan Z.H., Storm S., Lipton S.A. Greater sensitivity of larger retinal ganglion cells to NMDA-mediated cell death. Neuroreport. 5:1994;629-631.
10. Dreyer E.B., Zurakowski D., Schumer R.A., Podos S.M., Lipton S.A. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol. 114:1996;299-305.
11. Eitan S., Solomon A., Lavie V., Yoles E., Hirschberg D.L., Belkin M., Schwartz M. Recovery of visual response of injured adult rat optic nerves treated with transglutaminase. Science. 264:1994;1764-1768.
12. Faden A.I., Salzman S. Pharmacological strategies in CNS trauma. Trends Pharmacol. Sci. 13:1992;29-35.
13. Fisher J., Levkovitch-Verbin H., Schori H., Yoles E., Butovsky O., Kaye J.F., Ben-Nun A., Schwartz M. Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies. J. Neurosci. 21:2001;136-142.
14. E. Hauben, E. Agranov, A. Gothilf, U. Nevo, A. Cohen, I. Smirnov, L. Steinman, M. Schwartz, Post-traumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease, J. Clin. Invest. 108 (2001).
15. Hauben E., Butovsky O., Nevo U., Yoles E., Moalem G., Agranov E., Mor F., Leibowitz-Amit R., Pevsner E., Akselrod S., Neeman M., Cohen I.R., Schwartz M. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J. Neurosci. 20:2000;6421-6430.
16. Hauben E., Nevo U., Yoles E., Moalem G., Agranov E., Mor F., Akselrod S., Neeman M., Cohen I.R., Schwartz M. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet. 355:2000;286-287.
17. Hirschberg D.L., Yoles E., Belkin M., Schwartz M. Inflammation after axonal injury has conflicting consequences for recovery of function: rescue of spared axons is impaired but regeneration is supported [see comments]. J. Neuroimmunol. 50:1994;9-16.
18. Hauben E., Schwartz M. Therapeutic vaccination for spinal cord injury: helping the body to cure itself. Trends Pharmacol. Sci. 24:2003;7-12.
19. Kaufman P.L., Gabelt B.T., Cynader M. Introductory comments on neuroprotection. Surv. Ophthalmol. 43(Suppl. 1):1999;S89-S90.
20. Keirstead S.A., Rasminsky M., Fukuda Y., Carter D.A., Aguayo A.J., Vidal-Sanz M. Electrophysiologic responses in hamster superior colliculus evoked by regenerating retinal axons. Science. 246:1989;255-257.
21. Kipnis J., Yoles E., Porat Z., Cohen A., Mor F., Sela M., Cohen I.R., Schwartz M. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc. Natl. Acad. Sci. U.S.A. 97:2000;7446-7451.
22. Kipnis J., Yoles E., Schori H., Hauben E., Shaked I., Schwartz M. Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J. Neurosci. 21:2001;4564-4571.
23. Laquis S., Chaudhary P., Sharma S.C. The patterns of retinal ganglion cell death in hypertensive eyes. Brain Res. Bull. 784:1998;100-104.
24. Lazarov-Spiegler O., Solomon A.S., Schwartz M. Peripheral nerve-stimulated macrophages simulate a peripheral nerve-like regenerative response in rat transected optic nerve. Glia. 24:1998;329-337.
25. Kipnis J., Mizrahi T., Hauben E., Shaked I., Shevach E., Schwartz M. Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc. Natl. Acad. Sci. USA. 99:2002;15620-15625.
26. Kipnis J., Mizrahi T., Yoles E., Ben-Nun A., Schwartz M. Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity. J. Neuroimmunol. 130:2002;78-85.
27. Moalem G., Gdalyahu A., Shani Y., Otten U., Lazarovici P., Cohen I.R., Schwartz M. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J. Autoimmun. 15:2000;331-345.
28. Moalem G., Leibowitz-Amit R., Yoles E., Mor F., Cohen I.R., Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5:1999;49-55.
29. Moalem G., Monsonego A., Shani Y., Cohen I.R., Schwartz M. Differential T cell response in central and peripheral nerve injury: connection with immune privilege. FASEB J. 13:1999;1207-1217.
30. Moalem G., Yoles E., Leibowitz-Amit R., Muller-Gilor S., Mor F., Cohen I.R., Schwartz M. Autoimmune T cells retard the loss of function in injured rat optic nerves. J. Neuroimmunol. 106:2000;189-197.
31. Morrison J.C., Nylander K.B., Lauer A.K., Cepurna W.O., Johnson E. Glaucoma drops control intraocular pressure and protect optic nerves in a rat model of glaucoma. Invest. Ophthalmol. Vis. Sci. 39:1998;526-531.
32. Muir K.W., Lees K.R. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 26:1995;503-513.
33. Nakao N., Brundin P. Neurodegeneration and glutamate induced oxidative stress. Prog. Brain Res. 116:1998;245-263.
34. Netland P.A., Chaturvedi N., Dreyer E.B. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am. J. Ophthalmol. 115:1993;608-613.
35. Olney J.W. Excitatory transmitter neurotoxicity. Neurobiol. Aging. 15:1994;259-260.
36. Olney J.W. New mechanisms of excitatory transmitter neurotoxicity. J. Neural Transm. Suppl. 43:1994;47-51.
37. Quigley H.A., Nickells R.W., Kerrigan L.A., Pease M.E., Thibault D.J., Zack D.J. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest. Ophthalmol. Vis. Sci. 36:1995;774-786.
38. Rapalino O., Lazarov-Spiegler O., Agranov E., Velan G.J., Yoles E., Fraidakis M., Solomon A., Gepstein R., Katz A., Belkin M., Hadani M., Schwartz M. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat. Med. 4:1998;814-821.
39. Rowland L.P. Amyotrophic lateral sclerosis. Curr. Opin. Neurol. 7:1994;310-315.
40. Schori H., Kipnis J., Yoles E., WoldeMussie E., Ruiz G., Wheeler L.A., Schwartz M. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc. Natl. Acad. Sci. U.S.A. 98:2001;3398-3403.
41. Schwab M.E. Regeneration of lesioned CNS axons by neutralization of neurite growth inhibitors: a short review. J. Neurotrauma. 9(Suppl. 1):1992;S219-S221.
42. M. Schwartz, Physiological approaches to neuroprotection boosting of protective autoimmunity, Surv. Ophthalmol. 45 (Suppl. 3) (2001) S256-S260, discussion S273-S256.
43. Schwartz M., Belkin M., Yoles E., Solomon A. Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. J. Glaucoma. 5:1996;427-432.
44. Schwartz M., Cohen I.R. Autoimmunity can benefit self-maintenance. Immunol. Today. 21:2000;265-268.
45. Schwartz M., Moalem G., Leibowitz-Amit R., Cohen I.R. Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci. 22:1999;295-299.
46. Schwartz M., Yoles E. Neuroprotection: a new treatment modality for glaucoma? Curr. Opin. Ophthalmol. 11:2000;107-111.
47. Schwartz M., Yoles E., Levin L.A. 'Axogenic' and 'somagenic' neurodegenerative diseases: definitions and therapeutic implications. Mol. Med. Today. 5:1999;470-473.
48. Sucher N.J., Lipton S.A., Dreyer E.B. Molecular basis of glutamate toxicity in retinal ganglion cells. Vis. Res. 37:1997;3483-3493.
49. Vidal-Sanz M., Bray G.M., Villegas-Perez M.P., Thanos S., Aguayo A.J. Axonal regeneration and synapse formation in the superior colliculus by retinal ganglion cells in the adult rat. J. Neurosci. 7:1987;2894-2909.
50. Villegas-Perez M.P., Vidal-Sanz M., Bray G.M., Aguayo A.J. Influences of peripheral nerve grafts on the survival and regrowth of axotomized retinal ganglion cells in adult rats. J. Neurosci. 8:1988;265-280.
51. Weber A.J., Chen H., Hubbard W.C., Kaufman P.L. Experimental glaucoma and cell size, density, and number in the primate lateral geniculate nucleus. Invest. Ophthalmol. Vis. Sci. 41:2000;1370-1379.
52. Schwartz M., Kipnis J. Autoimmunity on alert: naturally occurring regulatory CD4+CD25+ T cells as part of the evolutionary compromise between a "need" and a "risk" Trends Immunol. 23:2002;530-534.
53. Schwartz M., Hauben E. Differing views on spinal cord repair. Science. 296:2002;1400.
54. Yoles E., Belkin M., Schwartz M. HU-211, a nonpsychotropic cannabinoid produces short- and long-term neuroprotection after optic nerve axotomy. J. Neurotrauma. 13:1996;49-57.
55. Yoles E., Friedmann I., Barouch R., Shani Y., Schwartz M. Self-protective mechanism awakened by glutamate in retinal ganglion cells. J. Neurotrauma. 18:2001;339-349.
56. Yoles E., Hauben E., Palgi O., Agranov E., Gothilf A., Cohen A., Kuchroo V., Cohen I.R., Weiner H., Schwartz M. Protective autoimmunity is a physiological response to CNS trauma. J. Neurosci. 21:2001;3740-3748.
57. Yoles E., Muller S., Schwartz M. NMDA-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush [published erratum appears in J. Neurotrauma 16 (4) (1999) 345]. J. Neurotrauma. 14:1997;665-675.
58. Yoles E., Schwartz M. Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies. Exp. Neurol. 153:1998;1-7.
59. Yoles E., Schwartz M. Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch. Ophthalmol. 116:1998;906-910.
60. Yoles E., Schwartz M. Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv. Ophthalmol. 42:1998;367-372.
61. Yoles E., Wheeler L.A., Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest. Ophthalmol. Vis. Sci. 40:1999;65-73.